Neurosterix announced a $105 million Series B financing on November 11, 2026. The round was led by RTW Investments, with participation from Janus Henderson, GV, Ikarian Capital, Affinity Asset Advisors and Dellora Investments, alongside existing investors Perceptive Advisors and Acorn Bioventures.
The main funding priority is NTX-253, an investigational muscarinic M4 positive allosteric modulator for schizophrenia. Neurosterix plans to advance it into Phase 2 after completing Phase 1 studies; it is not an approved treatment.
The company also named executives with Karuna Therapeutics experience, including Andrew Miller as executive chair, Edmund Harrigan as an independent director, and Stephen Brannan as chair of the clinical advisory board. Karuna developed KarXT, now marketed as Cobenfy.
The financing will also support Neurosterix’s other programs, including NTX-819 for mood and anxiety disorders and NTX-529 for psychosis- and mood-related disorders.
Sources:
Addex spinout Neurosterix raises $105M series B to fund phase 2 schizophrenia trial
Addex Spin-out Neurosterix Closes $105 Million Series B Financing
$105 Million to transform neuropsychiatric care by fine-tuning brain signaling
Neurosterix raises $105M to advance schizophrenia asset into Phase II
Press Release: Addex Spin-out Neurosterix Closes $105 Million...
Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
Addex Therapeutics Spin-Out Neurosterix Closes $105 Million Financing
Addex Therapeutics Ltd (ADXN) 6-K, filed Nov 12, 2026 - Equibles
Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy...
It’s not ‘Medicare for All,’ but ‘Medicare for More.’ What this could mean for workers over 50.